Leiomyosarcoma: Current Clinical Management and Future Horizons.
Surg Oncol Clin N Am
; 31(3): 527-546, 2022 07.
Article
in En
| MEDLINE
| ID: mdl-35715148
ABSTRACT
Leiomyosarcomas are soft tissue tumors that are derived from smooth muscle mainly in the pelvis and retroperitoneum. Percutaneous biopsy is paramount to confirm diagnosis. Imaging is necessary to complete clinical staging. Multimodal treatment should be directed by expert sarcoma multidisciplinary teams that see a critical volume of these rare tumors. Surgery is the mainstay of curative intent treatment; however due to its high metastatic progression, there may be a benefit for neoadjuvant systemic treatment. Adjuvant systemic treatment has no proven disease-free survival, and its main role is in the palliative setting to potentially prolong overall survival.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sarcoma
/
Soft Tissue Neoplasms
/
Leiomyosarcoma
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Surg Oncol Clin N Am
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Affiliation country:
Chile
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA